Taiwan’s Ministry of Health and Welfare has announced plans to allow cancer patients to receive chemotherapy at home, a shift that could reshape oncology care on the island. The initiative, disclosed by Health Minister Shih Chung-liang during a legislative session, hinges on resolving insurance coverage issues with the Financial Supervisory Commission (FSC), which convened a meeting with insurers yesterday to begin a comprehensive review of medical insurance claim rules. The focus is on adapting policies to cover patients transitioning from inpatient to home-based care, a move that reflects broader global trends toward decentralised treatment.

Viewed from Taipei, the proposal addresses a pressing need: many cancer patients with vascular access ports and stable conditions could avoid frequent hospital visits, reducing infection risks and improving quality of life. However, the success of home chemotherapy depends on whether insurers will reimburse the costs of drugs, nursing visits, and monitoring equipment. The FSC’s review, which analysts in London note mirrors similar debates in the UK’s National Health Service, must balance fiscal sustainability with patient access. Insurers are wary of expanding coverage without clear protocols for adverse events, such as allergic reactions or line infections, which could shift liability from hospitals to home-care providers.

From a regional perspective, Taiwan’s move aligns with trends in Japan and South Korea, where home-based cancer care has grown slowly due to regulatory hurdles. In contrast, the United States has seen rapid adoption of home infusion therapies, driven by Medicare reimbursement changes. Yet viewed from Washington, the Taiwanese approach is cautious: the government is prioritising a phased rollout, starting with patients who meet strict criteria, before expanding eligibility. This incremental strategy may reassure insurers but could frustrate patients eager for immediate access.

Looking ahead, the success of home chemotherapy in Taiwan will depend on the outcome of the FSC’s review, expected within months. If insurers agree to cover the service, the Ministry plans to pilot the programme in select hospitals before a nationwide launch. Analysts in Taipei caution that without robust telemedicine infrastructure and 24/7 nursing support, the initiative could strain resources. Nevertheless, the announcement signals a significant step toward patient-centred care, one that other Asian healthcare systems will watch closely as they grapple with ageing populations and rising cancer rates.